ClinicalTrials.govpublic full text
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
alzheimer's disease, rivastigmine transdermal, caregiver preference, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 843392
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.